• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管生成素样蛋白3缺失小鼠因脂蛋白脂肪酶活性增强而表现出血浆脂质浓度较低。

Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity.

作者信息

Fujimoto Kazunori, Koishi Ryuta, Shimizugawa Tetsuya, Ando Yosuke

机构信息

Medicinal Safety Research Laboratories, Sankyo Co., Ltd., Fukuroi, Shizuoka, Japan.

出版信息

Exp Anim. 2006 Jan;55(1):27-34. doi: 10.1538/expanim.55.27.

DOI:10.1538/expanim.55.27
PMID:16508209
Abstract

Angiopoietin-like 3 (ANGPTL3) is a secreted protein with both angiogenesis and lipid metabolism functions. We generated knockout mice that failed to express the Angptl3 gene, and analyzed the lipid metabolism. Angptl3-null mice, fed a normal diet or a high-fat, high-calorie (HFC) diet, revealed markedly low plasma lipid concentrations, especially plasma triglyceride concentration, although the body weight and liver weight were not different between Angptl3-null mice and wild-type mice. Angptl3-null mice fed an HFC diet also revealed a significantly reduced epididymal adipose tissue weight despite there being no difference in adipocyte size between them and wild-type mice. A triglyceride clearance study indicated that the lower plasma triglyceride concentration in Angptl3-null mice was caused by an accelerated clearance of triglyceride. In fact, lipoprotein lipase and hepatic lipase activities in the post-heparin plasma of Angptl3-null mice were 1.57 times and 1.42 times higher than those of wild-type mice, respectively. These results suggest that ANGPTL3 may have an effect not only on lipid metabolism but also on adipose formation.

摘要

血管生成素样3(ANGPTL3)是一种具有血管生成和脂质代谢功能的分泌蛋白。我们培育了无法表达Angptl3基因的基因敲除小鼠,并对其脂质代谢进行了分析。给Angptl3基因敲除小鼠喂食正常饮食或高脂、高热量(HFC)饮食后发现,尽管Angptl3基因敲除小鼠与野生型小鼠的体重和肝脏重量没有差异,但前者的血浆脂质浓度,尤其是血浆甘油三酯浓度显著降低。给喂食HFC饮食的Angptl3基因敲除小鼠的附睾脂肪组织重量也显著减轻,尽管它们与野生型小鼠的脂肪细胞大小没有差异。一项甘油三酯清除研究表明,Angptl3基因敲除小鼠血浆甘油三酯浓度较低是由于甘油三酯清除加速所致。事实上,Angptl3基因敲除小鼠肝素后血浆中的脂蛋白脂肪酶和肝脂肪酶活性分别比野生型小鼠高1.57倍和1.42倍。这些结果表明,ANGPTL3可能不仅对脂质代谢有影响,而且对脂肪形成也有影响。

相似文献

1
Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity.血管生成素样蛋白3缺失小鼠因脂蛋白脂肪酶活性增强而表现出血浆脂质浓度较低。
Exp Anim. 2006 Jan;55(1):27-34. doi: 10.1538/expanim.55.27.
2
ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase.血管生成素样蛋白3通过抑制脂蛋白脂肪酶降低极低密度脂蛋白甘油三酯清除率。
J Biol Chem. 2002 Sep 13;277(37):33742-8. doi: 10.1074/jbc.M203215200. Epub 2002 Jul 3.
3
A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.血管生成素样蛋白3表达降低对载脂蛋白E缺陷小鼠的动脉粥样硬化具有保护作用。
J Lipid Res. 2003 Jun;44(6):1216-23. doi: 10.1194/jlr.M300031-JLR200. Epub 2003 Apr 1.
4
Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo.血管生成素样3(ANGPTL3)中对脂质代谢调节重要的蛋白质区域:ANGPTL3在体内被切割并激活。
J Biol Chem. 2003 Oct 24;278(43):41804-9. doi: 10.1074/jbc.M302861200. Epub 2003 Aug 8.
5
Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.血管生成素样蛋白 3 缺乏与胰岛素敏感性增加、脂蛋白脂肪酶活性增加和血清游离脂肪酸减少有关。
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1706-13. doi: 10.1161/ATVBAHA.113.301397. Epub 2013 May 9.
6
[Angptl3(angiopoietin-like 3)].[血管生成素样蛋白3(Angptl3)]
Nihon Rinsho. 2004 Jun;62(6):1170-4.
7
Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism.转基因血管生成素样蛋白(angptl)4过表达以及angptl4和angptl3的靶向破坏:甘油三酯代谢的调节
Endocrinology. 2005 Nov;146(11):4943-50. doi: 10.1210/en.2005-0476. Epub 2005 Aug 4.
8
Hepatic ANGPTL3 regulates adipose tissue energy homeostasis.肝脏血管生成素样蛋白3调节脂肪组织能量稳态。
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11630-5. doi: 10.1073/pnas.1515374112. Epub 2015 Aug 24.
9
Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes.血管生成素样蛋白3,一种肝脏分泌因子,可激活脂肪细胞中的脂肪分解。
Biochem Biophys Res Commun. 2003 Feb 7;301(2):604-9. doi: 10.1016/s0006-291x(02)03058-9.
10
ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.血管生成素样蛋白3(ANGPTL3)是导致乳腺炎小鼠血脂异常的主要机制的一部分,主要是通过抑制脂蛋白脂肪酶(LPL)来实现的。
Exp Mol Pathol. 2017 Dec;103(3):242-248. doi: 10.1016/j.yexmp.2017.11.003. Epub 2017 Nov 9.

引用本文的文献

1
ANGPTL4: A Comprehensive Review of 25 Years of Research.血管生成素样蛋白4:25年研究综述
Cancers (Basel). 2025 Jul 16;17(14):2364. doi: 10.3390/cancers17142364.
2
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study.依维那单抗治疗纯合子家族性高胆固醇血症:ELIPSE HoFH研究的意大利队列
Adv Ther. 2025 May;42(5):2465-2479. doi: 10.1007/s12325-025-03160-4. Epub 2025 Apr 2.
3
ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states.血管生成素样蛋白3(ANGPTL3)根据细胞生长状态调节SmarcAL1向过氧化物酶体的转运。
Sci Rep. 2025 Feb 11;15(1):5036. doi: 10.1038/s41598-025-89552-6.
4
Circumventing Cardiovascular Calamities: The Dawn of ANGPTL3 Blockade in Severe Dyslipidemia Management.规避心血管灾难:ANGPTL3 阻断在严重血脂异常管理中的黎明。
Cardiovasc Hematol Disord Drug Targets. 2024;24(2):59-64. doi: 10.2174/011871529X305291240715112812.
5
The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.依维那库单抗治疗纯合子家族性高胆固醇血症患者的长期疗效和安全性
JACC Adv. 2023 Oct 11;2(9):100648. doi: 10.1016/j.jacadv.2023.100648. eCollection 2023 Nov.
6
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.依洛尤单抗治疗纯合子家族性高胆固醇血症:长期安全性和疗效。
Eur Heart J. 2024 Jul 12;45(27):2422-2434. doi: 10.1093/eurheartj/ehae325.
7
A unified model for regulating lipoprotein lipase activity.调控脂蛋白脂肪酶活性的统一模型。
Trends Endocrinol Metab. 2024 Jun;35(6):490-504. doi: 10.1016/j.tem.2024.02.016. Epub 2024 Mar 23.
8
Zebrafish ApoB-Containing Lipoprotein Metabolism: A Closer Look.斑马鱼载脂蛋白 B 脂蛋白代谢:深入观察。
Arterioscler Thromb Vasc Biol. 2024 May;44(5):1053-1064. doi: 10.1161/ATVBAHA.123.318287. Epub 2024 Mar 14.
9
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.用于一级和二级心血管预防的既定和新兴降脂药物。
Am J Cardiovasc Drugs. 2023 Sep;23(5):477-495. doi: 10.1007/s40256-023-00594-5. Epub 2023 Jul 24.
10
A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.靶向 LDL 受体依赖性和非依赖性通路治疗高胆固醇血症的研究进展述评,高胆固醇血症是 ASCVD 的主要危险因素之一。
Cells. 2023 Jun 16;12(12):1648. doi: 10.3390/cells12121648.